Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma

Phase 1

Completed

Conditions: Hodgkin's Lymphoma

Interventions: Drug: Panobinostat
Drug: Ifosfamide
Drug: Mesna
Drug: Carboplatin
Drug: Etoposide
Drug: Pegfilgrastim

First Posted Date: 2010-07-26

Last Posted Date: 2021-01-06

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 62

Registration Number: NCT01169636

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)

Phase 2

Completed

Conditions: CLL
Leukemia

Interventions: Drug: Eltrombopag

First Posted Date: 2010-07-23

Last Posted Date: 2023-03-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 23

Registration Number: NCT01168921

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies

Phase 1

Terminated

Conditions: Lung Cancer
Non-small Cell Lung Cancer
Carcinoid
Small Cell Lung Cancer
Thymic Cancer

Interventions: Radiation: Proton Therapy

First Posted Date: 2010-07-20

Last Posted Date: 2020-01-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT01165658

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer

Phase 1

Completed

Conditions: Bladder Cancer

Interventions: Drug: SCH 721015

First Posted Date: 2010-07-15

Last Posted Date: 2016-11-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 7

Registration Number: NCT01162785

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML)

Phase 1

Terminated

Conditions: Acute Myelogenous Leukemia

Interventions: Drug: Plerixafor
Drug: Clofarabine

First Posted Date: 2010-07-12

Last Posted Date: 2019-08-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 22

Registration Number: NCT01160354

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Molecular Triaging of Newly Diagnosed Breast Cancer

Not Applicable

Withdrawn

Conditions: Breast Cancer

Interventions: Drug: Paclitaxel
Drug: Fluorouracil
Drug: Doxorubicin
Drug: Epirubicin
Drug: Cyclophosphamide
Drug: Bevacizumab

First Posted Date: 2010-07-09

Last Posted Date: 2012-07-31

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT01159236

Utility of Vancomycin Loading: A Pharmacokinetic Analysis in Critically Ill Patients

Not Applicable

Terminated

Conditions: Infection

Interventions: Drug: Vancomycin

First Posted Date: 2010-07-07

Last Posted Date: 2013-03-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1

Registration Number: NCT01157533

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 2

Active, not recruiting

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: Docetaxel
Drug: Cetuximab
Drug: Cisplatin
Radiation: Radiotherapy (RT)
Drug: Fluorouracil
Other: Chemotherapy

First Posted Date: 2010-07-01

Last Posted Date: 2025-05-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 128

Registration Number: NCT01154920

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Bendamustine and Bevacizumab for Advanced Cancers

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: Bendamustine
Drug: Bevacizumab

First Posted Date: 2010-06-29

Last Posted Date: 2015-11-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 59

Registration Number: NCT01152203

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and Bortezomib

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: FLT-PET

First Posted Date: 2010-06-14

Last Posted Date: 2022-01-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 3

Registration Number: NCT01143779

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy